Surgical management of hepatocellular carcinoma

Author:

Details:

Discipline of Surgery, University of Sydney, NSW and Department of Surgery, Westmead Hospital, New South Wales, Australia


Abstract

Hepatocellular carcinoma (HCC) is among the three most common causes of cancer death worldwide. Liver resection and liver transplantation are regarded as the standard curative treatment for hepatocellular carcinoma. Although liver transplantation for early stage hepatocellular carcinoma has been shown to have excellent long-term survival outcomes and low recurrence rates, the shortage of donor liver grafts limits its wide application. Liver resection can be safely performed in patients with early stage hepatocellular carcinoma and preserved liver function. Although postoperative recurrence after liver resection of hepatocellular carcinoma is almost universal, the reported five-year overall survival rates are around 50%. Recently, the concept of primary liver resection and salvage liver transplantation has been proposed in patients with early stage hepatocellular carcinoma and preserved liver function. Universal adoption of either liver resection or liver transplantation for hepatocellular carcinoma is unwarranted and overly simplistic. The use of different therapeutic approaches that incorporate liver resection or liver transplantation, depends not only on the availability of donor liver grafts and waiting time, but also on the expertise of individual centres.


Hepatocellular carcinoma (HCC) is a major health problem worldwide with an estimated incidence of 500,000 new cases every year.1 It is among the three most common causes of cancer death worldwide, accounting for about 315,000 deaths annually.2 Although it is predominantly a cancer found in the east, its incidence in the west has recently doubled and is predicted to double again over the next 20 years.3,4 This phenomenon is largely explained by the emerging burden of hepatitis B and C viral infection. Liver resection and liver transplantation are regarded as the standard curative treatments for HCC.5 It is now well established that liver transplantation is the treatment of choice for unresectable early stage HCC in patients with decompensated cirrhosis.6-8 The best treatment strategy for early stage HCC in patients with preserved liver function remains controversial.

Liver resection

With the increased understanding of liver segmental anatomy and the improvements in surgical techniques and peri-operative care, there has been a dramatic reduction in peri-operative mortality and an improvement in survival outcomes after liver resection for HCC in the past two decades.9 In recent series from the east and the west, a peri-operative mortality rate of less than 5% and a five-year overall survival rate of 40%-50% has been reported.10-12 However, a high incidence of post-operative recurrence is universal and continues to be the major cause of late deaths. The cumulative five-year recurrence rate is in the range of 75% to 100%.13 Recurrence occurs in the liver remnant in 78%-96% of cases as a result of either intrahepatic metastasis from the primary tumour or multicentric occurrence.13

Most patients with HCC have underlying cirrhosis. Liver resection for HCC in the presence of cirrhosis is associated with a significant risk of morbidity and mortality. Careful patient selection for liver resection is therefore paramount to avoid post-operative liver failure and death. This involves an adequate assessment of the tumour extent, the severity of the underlying liver disease and the functional liver reserve. Only 10-37% of patients with HCC are amenable to liver resection at the time of diagnosis.9,11,14 A recent study from Australia showed that liver resection and liver transplantation were the primary treatment in only 17% and 16% of the total cohort of 235 patients with HCC respectively.15 In general, large tumour size with insufficient liver remnant after liver resection, extensive and multifocal bilobar tumours, extrahepatic metastases and tumours with main portal vein thrombous or hepatic vein/inferior vena cava involvement, are all considered a contraindication to liver resection.5

Preoperative assessment of liver function

Because HCC is associated with varying degrees of liver disease, inadequate functional liver reserve after liver resection is always a concern. Determination of the amount of liver that can be safely resected is multi-factorial and depends on the extent of cirrhosis, the functional liver remnant/reserve and the regenerative response following liver resection. In general, a normal liver can tolerate the resection of up to 75% of functional liver parenchyma.16 On the other hand, the risk of postoperative liver failure and subsequent death are high after major liver resection in patients with cirrhosis.

Pre-operative assessment of liver function and prediction of post-operative functional liver remnant/reserve are of paramount importance to minimise the risk of post-operative liver failure. Measurement of the volume of liver remnant by CT volumetry has been shown to be helpful in selecting patients for major liver resection.17 Vauthey et al demonstrated that small liver remnant volume was associated with worse post-operative liver function and a higher complication rate after extended hepatectomy.18 On the other hand, Child-Pugh classification (table 1) is the most simple, widely used and reproducible method to identify the patient at risk of liver failure after liver resection.19 In general, Child-Pugh class A patients can be considered for resection of up to 50% of the liver parenchyma, whereas Child-Pugh class B patients tolerate resections up to 25%. Patients with Child-Pugh class C cirrhosis are considered as an absolute contraindication for liver resection.5 Numerous quantitative liver function tests have also been developed and evaluated. However, none of these tests on its own can take into account the complexities of liver failure, nor has been demonstrated to be clearly superior to another in predicting post-operative outcome after liver resection for HCC.5 In the east, indocyanine green clearance at 15 minutes (ICG15) is the most commonly used quantitative assessment of liver function. The value of ICG15 >20% precludes major liver resection.20,21 In the west, selection of candidates for liver resection is often based on the presence of portal hypertension in addition to the Child-Pugh classification.22

Clinically relevant portal hypertension is defined as the presence of a hepatic vein pressure gradient (HVPG) ≥10mmHg, the presence of oesophageal varices or splenomegaly with a platelet count less than 100×109/L. Bruix et al demonstrated that HVPG ≥10mmHg was associated with postoperative liver failure in patients with HCC and Child-Pugh class A cirrhosis.23 Recently, the model for end-stage liver disease (MELD) score has been shown to be an accurate predictor of postoperative liver failure and death after liver resection. Patients with a MELD score <9 had a reported zero perioperative mortality after liver resection for HCC.24,25

Table 1

Portal vein embolisation

Because most patients with HCC have impaired functional liver reserve due to hepatitis B or C virus-associated cirrhosis, the amount of liver parenchyma that can be safely resected is limited. In selected patients with a small liver remnant, attempts have been made to improve on the safety of liver resection by redirecting portal blood flow toward the segment of liver that will remain in situ after liver resection.26 Pre-operative portal vein embolisation (PVE) induces atrophy of the embolised segments and compensatory hypertrophy of the unembolised segments of the liver (figure 1). PVE can be performed using an open transileocolic approach, percutaneous transhepatic contralateral approach or percutaneous transhepatic ipsilateral approach. These approaches are chosen on the basis of the type of resection planned, the location of the tumour and the available surgical and radiological expertise.27 In general, PVE is indicated in patients with a predicted functional liver remnant of <25% in non-cirrhotic patients, or <40% in patients with cirrhosis.16,28 A recent meta-analysis has shown that PVE is safe and effective in inducing liver hypertrophy to prevent liver failure after liver resection due to insufficient functional liver remnant.27 PVE has also been shown to increase the resectability of HCC with comparable long-term survival outcomes.29-32

Figure 1 Right portal vein embolism

Liver resection for large or multinodular HCC

Several prognostic staging models have been developed to predict survival and to assess the survival outcomes of HCC treatment.5 The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used in the west and stratifies patients with HCC into four categories – early, intermediate, advanced and terminal.33 It has been recently integrated into the American Association for the Study of Liver Diseases and the European Association for the Study of Liver guidelines on the management of HCC.34,35 The BCLC staging system recommends different treatment options for each stage of the disease.36 Liver resection is indicated only in patients with early stage HCC, as defined by, within the Milan criteriaa: a single HCC ≤5cm in diameter or up to 3 HCCs ≤3cm in diameter;8 normal clinical performance status; and preserved liver function (absence of clinical portal hypertension and Child-Pugh class A status). There is no doubt that patients with early stage HCC have excellent prognosis after liver resection. Although large tumour size (>5cm) and multiple tumour nodules have been shown to be less favourable prognostic factors for patients with HCC, liver resection remains the only hope of cure in patients with large or multinodular HCC outside the Milan criteria.37 Previous studies have shown that up to 50% of patients with HCC who underwent liver resection had disease classified as being intermediate or advanced stage according to the BCLC algorithm.38,39 In a multi-institutional study, Ng et al demonstrated that liver resection could be safely performed in patients with large or multinodular HCC, providing the functional liver reserve is acceptable. A five-year overall survival of 39% and a five-year disease free survival rate of 26% could be achieved.38

Liver transplantation

The first successful liver transplant for HCC was performed on a 19 month-old girl by Starzl and his team in July 1967.40 In theory, liver transplantation is a better treatment option than liver resection as it simultaneously removes the tumour, the underling cirrhosis and cures the portal hypertension. Early experience with liver transplantation for HCC was, however, associated with a high tumour recurrence rate and poor long-term survival.41,42 These poor results were presumably due to the broad selection criteria used, with inclusion of extensive and bulky tumours two decades ago. In 1996, Mazzaferro et al published a landmark paper in which they validated the tumour characteristics associated with superior survival outcome following liver transplantation.8 The four-year overall and disease-free survival rates were 85% and 92% respectively with a tumour recurrence rate of 8.3%. These constitute the Milan criteria – a single HCC ≤5cm in diameter or up to three HCCs ≤3cm in diameter. These results are comparable with those of non-cancer liver transplant recipients. To push the boundary further, the University of California San Francisco (UCSF) group demonstrated that size criteria could be expanded without compromising the survival outcome.43 The UCSF criteria consist of single HCC ≤6.5cm or up to three HCCs with the largest tumour ≤4.5cm and total tumour diameter ≤8 cm, without gross vascular invasion. One-year and five-year overall survival rates of 90% and 75.2%, with tumour recurrence rates of 11.4% were reported. Chen et al analysed and validated these excellent survival outcomes of liver transplantation for HCC in Australia and New Zealand.44 One-year and five-year overall survival rates were 88% and 74% respectively in patients within the Milan criteria, and 87% and 73% respectively in patients within the UCSF criteria. In patients outside the USCF criteria, the survival outcomes were poor, with one-year and five-year survival rates of 71% and 36% respectively.

Although tumour recurrence is much less a problem after liver transplantation for HCC within the Milan or UCSF criteria, there are other complications specific to transplantation that compromise long-term survival, such as graft rejection, opportunistic infections and the development of other malignancies as a result of immunosuppression.45 In addition, the major drawback of liver transplantation for the treatment of HCC is the scarcity of deceased organ donors. Many patients with HCC either die before the organ becomes available or drop out from the transplant waiting list because of tumour progression. The dropout rate can be as high as 25% to 37.8% in 12 months.46,47 It has also been shown that the results of liver transplantation were adversely affected by increasing waiting times with a two-year intention-to-treat survival falling from 84% for 62 days of waiting time, to 54% for 162 days of waiting time.48 The survival benefit of liver transplantation over liver resection has been shown to disappear once the waiting time for a donor liver graft exceeds six months.49

A variety of bridging therapies, such as transarterial chemoembolisation and radiofrequency ablation, have been advocated as a means to address the prolonged waiting time.50 In theory, these therapies slow down tumour progression, decrease tumour cell dissemination during recipient total hepatectomy and lower the risk of post-operative recurrence. While some studies demonstrated favourable results of bridging therapies in decreasing the drop-out rate, others reported similar drop-out rates of 15% at six months and 25% at 12 months, but longer waiting times for liver transplantation.46,51,52 Although most transplant physicians and surgeons would agree that bridging therapy is useful, there is currently no evidence to support its use. Future studies are required to confirm the efficacy of bridging therapies before liver transplantation for HCC. The questions of which therapy and when to commence the therapy, also require further evaluation.50

Live donor liver transplantation

As a consequence of deceased donor shortage, live donor liver transplantation (LDLT) for adults has developed as an alternative over the past decade.53 The shortage of deceased donor liver grafts is particularly severe in the east. The deceased donor rates are fewer than five donors per million in the east, compared with those of 10 to 35 donors per million population in the west.54 With HCC being the most common cancer and the most frequent indication for liver transplantation in the east, the enthusiasm for LDLT therefore continues to surge. In theory, LDLT can provide an unlimited source of donor liver grafts and eliminate the uncertainty of prolonged waiting times and the risk of dropout due to tumour progression.55 Using a decision analytical model taking into account the risk of dropout while waiting (4% per month), the expected survival of the recipient (70% at five years) and the risk for the donor (0.3% to 0.5% mortality), Sarasin et al demonstrated that patients with HCC waiting more than seven months for a deceased donor liver would benefit from LDLT.56 Previous studies on LDLT for HCC also demonstrated favourable long-term survival outcomes.57,58 However, the question of whether the outcome after LDLT for HCC is comparable with that of deceased donor liver transplantation remains unclear.53

More importantly, LDLT poses an ethical dilemma to all transplant physicans and surgeons – ‘First do no harm’.59 Donor hepatectomy is a surgical procedure that subjects a healthy volunteer to a major operation with 20% morbidity and 0.5% mortality, without direct therapeutic benefits.60 Currently, LDLT remains a novel treatment for HCC with unresolved issues regarding indications and results.

Liver resection v liver transplantation

The superiority of liver transplantation over liver resection remains a topic of debate. In specific clinical circumstances, it is clear that liver transplantation may be the only option, namely for patients with early stage HCC that clearly do not have sufficient functional liver reserve to tolerate liver resection. On the other hand, liver resection may be the only curative option in patients with large HCC without cirrhosis. The controversy remains over the management of patients with early stage HCC and well compensated cirrhosis that would tolerate liver resection or transplantation.61 There are no randomised control trials that directly compare the two modalities.

Using the best available evidence, patients with early stage HCC who are eligible for either liver resection or transplantation, have a better survival with liver transplantation than resection. The tumour recurrence rates are also significantly lower in the liver transplantation group.6,62,63 Therefore, in an ideal world with unlimited organs, liver transplantation would offer improved oncologic outcomes over liver resection. However, because of the growing shortage of donor liver grafts throughout the world, the superior outcomes of liver transplantation may be significantly compromised by patients dropping out of the transplant waiting list, largely from tumour progression. Recently, the concept of primary liver resection and salvage liver transplantation has been proposed in patients with early stage HCC and preserved liver function. It has been shown to be a feasible strategy, as up to 80% of patients with tumour recurrence after liver resection may still be amenable to liver transplantation.6,63 Salvage liver transplantation has also been shown to be as safe and efficacious as primary liver transplantation, with no difference in morbidity and perioperative mortality. In addition, the long-term survival outcomes are comparable.64

In summary, universal adoption of either liver resection or liver transplantation for HCC is unwarranted and overly simplistic. The use of different therapeutic approaches that incorporate liver resection or transplantation should be dictated by the clinical and local situation. Factors will include not only medical and surgical expertise, donor graft availability and anticipated waiting times, but also patient and tumour specific factors.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.

2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Seminars in Liver Disease. 1999;19(3):271-285.

3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750.

4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350(9085):1142-1143.

5. Lau W-Y, Lai ECH. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008;7(3):237-257.

6. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373-382.

7. Fan ST, Cheung ST, Lo CM. Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15 Suppl: E181-186.

8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.

9. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229(3):322-330.

10. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519-524.

11. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229(6):790-799;discussion 799-800.

12. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001;234(1):63-70.

13. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10-24.

14. Colella G, Bottelli R, De Carlis L, Sansalone CV, Rondinara GF, Alberti A, et al. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization. Transpl Int. 1998;11 Suppl 1:S193-196.

15. Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, et al. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int. 2007;27(9):1240-1248.

16. de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V. Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology. 1996;24(6):1386-1391.

17. Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26(5):1176-1181.

18. Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000;127(5):512-519.

19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.

20. Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg. 1999;86(8):1012-1017.

21. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl. 2004;10(2 Suppl 1):S39-45.

22. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-37.

23. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111(4):1018-1022.

24. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006;12(6):966-971.

25. Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9(9):1207-1215;discussion 1215.

26. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10(5):803-808.

27. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49-57.

28. Ribero D, Curley SA, Imamura H, Madoff DC, Nagorney DM, Ng KK, et al. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol. 2008;15(4):986-992.

29. Wakabayashi H, Ishimura K, Okano K, Izuishi K, Karasawa Y, Goda F, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer. 2001;92(9):2384-2390.

30. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237(2):208-217.

31. Azoulay D, Castaing D, Krissat J, Smail A, Hargreaves GM, Lemoine A, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232(5):665-672.

32. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237(5):686-691;discussion 691-683.

33. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.

34. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005;42(5): 1208-1236.

35. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. HCC EPoEo. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421-430.

36. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer G. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115-120.

37. Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol. 2001;19(12):3037-3044.

38. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. International Cooperative Study Group on Hepatocellular C. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol. 2005;12(5):364-373.

39. Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg. 2008;143(11):1082-1090.

40. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, et al. Orthotopic homotransplantation of the human liver. Ann Surg. 1968;168(3):392-415.

41. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991;110(4):726-734;discussion 734-725.

42. Pichlmayr R, Weimann A, Ringe B. Indications for liver transplantation in hepatobiliary malignancy. Hepatology. 1994;20(1 Pt 2):33S-40S.

43. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-1403.

44. Chen JC, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, et al. Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB. In press 2009.

45. Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J Hepatol. 2003;39(5):664-678.

46. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl. 2004;10(3):449-455.

47. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl. 2004;10(5):621-630.

48. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434-1440.

49. Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998;28(2):436-442.

50. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 2005;80(1 Suppl):S113-119.

51. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg. 2004;240(5):900-909.

52. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9(6):557-563.

53. Mazzaferro V, Chun YS, Poon RTP, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15(4):1001-1007.

54. de Villa VH, Lo CM, Chen CL. Ethics and rationale of living-donor liver transplantation in Asia. Transplantation. 2003;75(3 Suppl):S2-5.

55. Lo CM, Fan ST. Liver transplantation for hepatocellular carcinoma. Br J Surg. 2004;91(2):131-133.

56. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology. 2001;33(5):1073-1079.

57. Todo S, Furukawa H, Japanese Study Group on Organ T. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004;240(3):451-459;discussion 459-461.

58. Lo CM, Fan ST, Liu CL, Chan SC, Wong J. The role and limitation of living donor liver transplantation or hepatocellular carcinoma. Liver Transpl. 2004;10(3):440-447.

59. Fan ST. Live donor liver transplantation in adults. Transplantation. 2006;82(6):723-732.

60. Chan SC, Fan ST, Lo CM, Liu CL, Wong J. Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Ann Surg. 2007;245(1):110-117.

61. Majno P, Mentha G, Mazzaferro V. Resection, transplantation, either, or both? Other pieces of the puzzle. Liver Transpl. 2005;11(10):1177-1180.

62. Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl. 2005;11(10):1242-1251.

63. Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238(3):315-321;discussion 321-313.

64. Belghiti J, Cortes A, Abdalla EK, Regimbeau J-M, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg. 2003;238(6):885-892;discussion 892-883.

Be the first to know when a new issue is online. Subscribe today.